This multi-center Phase I study is designed to characterize the PK and PD of F/TAF oral
tablets to assess systemic and genital tract bioavailability in healthy women. The oral
tablets to be used in the study are F/TAF (200/10 mg), F/TAF (200/25 mg) and F/TDF (200/300
mg, Truvada). Samples will be obtained before, during and after dosing in two study phases.